

References

I-126

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2021.
2. The American Thoracic Society. American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with Alpha-1 antitrypsin deficiency.
3. Henao M, Craig T. Understanding alpha-1 antitrypsin deficiency: A review with an allergist's outlook. *Allergy And Asthma Proceedings*. 2017; 38(2):98-107.
4. Vogelmeier C, Criner G, Agustí A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *American Journal Of Respiratory And Critical Care Medicine*. 2017; 195(5):557-582.
5. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: Safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
6. MCGTM Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
7. Micromedex DrugDex Compendium®. 2024. Alpha-1 Proteinase Inhibitors.
8. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Alpha-1 Proteinase Inhibitors.
9. Kueppers F, Andrade MD, Xu Q, Dunbrack RL, Kim J, Sanders CL. Protein modeling to assess the pathogenicity of rare variants of SERPINA1 in patients suspected of having Alpha 1 Antitrypsin Deficiency. *BMC Med Genet*. 2019. 20(1):125.
10. Wells AD, Woods A, Hilleman DE, Malesker MA. Alpha-1 antitrypsin replacement in patients with COPD. P&T: A Peer-Reviewed Journal for Managed Care & Formulary Management. 2019;44(7):412-415.
11. Brantly ML, Lascano JE, Shahmohammadi A. Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence. *Chronic Obstr Pulm Dis*. 2019;6(1):100-114.
12. Glassia (Alpha1-proteinase inhibitor (human)) [package insert]. Baxalta US Inc. Lexington, MA. Revised 09/2023.
13. Prolastin-C Liquid (Alpha1-proteinase inhibitor [human]) [package insert]. Grifols Therapeutics, LLC. Research Triangle Park, NC. Revised 05/2020.
14. Aralast (Alpha1-proteinase inhibitor (human)) [package insert]. Baxalta U.S. Inc., Lexington, MA. Revised 03/2023.
15. Zemaira (Alpha1-proteinase inhibitor (human)) [package insert]. CSL Behring, LLC. Kankakee, IL. Revised 09/2022.
16. [Alpha 1-Proteinase Inhibitor (Human)] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 1, 2009.
17. Franciosi AN, Ralph J, O'Farrell NJ, et al. Alpha-1 antitrypsin deficiency-associated panniculitis. *J Am Acad Dermatol*. 2022;87(4):825-832.

18. Li Z, Franke RM, Morris DN, Yel L. Pharmacokinetics and Biochemical Efficacy of an α 1-Proteinase Inhibitor (Aralast NP) in α 1-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis. *Pulm Ther.* 2022;8(3):311-326.